Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India
Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced...